DOP2021000001A - Nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina - Google Patents

Nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina

Info

Publication number
DOP2021000001A
DOP2021000001A DO2021000001A DO2021000001A DOP2021000001A DO P2021000001 A DOP2021000001 A DO P2021000001A DO 2021000001 A DO2021000001 A DO 2021000001A DO 2021000001 A DO2021000001 A DO 2021000001A DO P2021000001 A DOP2021000001 A DO P2021000001A
Authority
DO
Dominican Republic
Prior art keywords
acid addition
addition salt
sulfonyl
new
nmethylmethanamine
Prior art date
Application number
DO2021000001A
Other languages
English (en)
Inventor
Kim Aeri
Hyung; Cho Kwan
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/KR2017/002913 external-priority patent/WO2017164575A1/en
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of DOP2021000001A publication Critical patent/DOP2021000001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención proporciona una nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1H–pirrol–3–il)–N–metilmetanamina. La sal de adición de ácido arriba descripta puede tener no solo excelente actividad inhibitoria de la bomba protónica, actividad inhibitoria del daño gástrico y efecto mejorador de factores defensivos, sino, además, excelente actividad de erradicación contra H. pylori, y por lo tanto, puede usarse eficazmente para la prevención y el tratamiento de lesión gastrointestinal debida a úlcera del tracto gastrointestinal, gastritis, esofagitis por reflujo, o H. pylori.
DO2021000001A 2016-03-25 2021-01-06 Nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina DOP2021000001A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160036081 2016-03-25
KR1020170018336A KR20170113040A (ko) 2016-03-25 2017-02-09 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
PCT/KR2017/002913 WO2017164575A1 (en) 2016-03-25 2017-03-17 Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine

Publications (1)

Publication Number Publication Date
DOP2021000001A true DOP2021000001A (es) 2021-03-15

Family

ID=60141235

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2018000191A DOP2018000191A (es) 2016-03-25 2018-08-31 Nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina
DO2021000001A DOP2021000001A (es) 2016-03-25 2021-01-06 Nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2018000191A DOP2018000191A (es) 2016-03-25 2018-08-31 Nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina

Country Status (29)

Country Link
US (1) US10487053B2 (es)
EP (1) EP3433232B1 (es)
JP (1) JP6609065B2 (es)
KR (2) KR20170113040A (es)
CN (1) CN108602771B (es)
AR (1) AR107964A1 (es)
AU (1) AU2017238917B2 (es)
CA (1) CA3014753C (es)
CL (1) CL2018002415A1 (es)
CO (1) CO2018008834A2 (es)
DO (2) DOP2018000191A (es)
ES (1) ES2811478T3 (es)
HK (1) HK1254394A1 (es)
HR (1) HRP20201571T1 (es)
HU (1) HUE053741T2 (es)
JO (1) JOP20170071B1 (es)
MA (1) MA43832B1 (es)
MX (1) MX379775B (es)
MY (1) MY196355A (es)
NZ (1) NZ745267A (es)
PE (1) PE20190169A1 (es)
PH (1) PH12018501845B1 (es)
PL (1) PL3433232T3 (es)
PT (1) PT3433232T (es)
RS (1) RS60857B1 (es)
SG (1) SG11201806968RA (es)
SI (1) SI3433232T1 (es)
TN (1) TN2018000269A1 (es)
TW (1) TWI607753B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
EP4079293A4 (en) * 2019-12-18 2024-01-03 Daewoong Pharmaceutical Co., Ltd. LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANEAMINE
EP4148050B1 (en) * 2020-06-17 2024-12-18 Ildong Pharmaceutical Co., Ltd. Novel acid secretion inhibitor and use thereof
WO2022131844A1 (ko) * 2020-12-18 2022-06-23 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 경구투여용 제제
AU2022280595B2 (en) * 2021-05-26 2024-11-14 Daewoong Pharmaceutical Co., Ltd. Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
US20240261261A1 (en) * 2021-05-26 2024-08-08 Daewoong Pharmaceutical Co., Ltd. New formulation for injection comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
WO2023113474A1 (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2023113458A1 (en) * 2021-12-15 2023-06-22 Ildong Pharmaceutical Co., Ltd. Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
TW202411215A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
KR20240170934A (ko) * 2022-05-23 2024-12-05 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法
KR20240127136A (ko) * 2023-02-15 2024-08-22 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101178747B1 (ko) * 2004-09-30 2012-09-03 다케다 야쿠힌 고교 가부시키가이샤 프로톤 펌프 저해제
HRP20110473T1 (hr) 2005-08-30 2011-07-31 Takeda Pharmaceutical Company Limited Supstituirani derivati 1-heterociklilsulfonil, 2-aminometil, 5-(hetero)-aril 1-h-pirola kao inhibitori kiselinske sekrecije
CA2647862A1 (en) 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2014075575A1 (zh) * 2012-11-19 2014-05-22 江苏豪森药业股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105143187B (zh) * 2013-02-28 2018-04-03 武田药品工业株式会社 制备磺酰氯化合物的方法
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN104447491B (zh) 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
SG11201806968RA (en) 2018-09-27
JOP20170071B1 (ar) 2021-08-17
PH12018501845B1 (en) 2022-02-18
NZ745267A (en) 2020-03-27
CO2018008834A2 (es) 2018-10-10
HUE053741T2 (hu) 2021-07-28
CN108602771B (zh) 2021-07-16
TW201737908A (zh) 2017-11-01
CA3014753C (en) 2023-08-29
PT3433232T (pt) 2020-07-21
MX2018009220A (es) 2018-09-10
US20190031609A1 (en) 2019-01-31
AU2017238917B2 (en) 2019-07-11
MX379775B (es) 2025-03-11
SI3433232T1 (sl) 2020-10-30
TWI607753B (zh) 2017-12-11
US10487053B2 (en) 2019-11-26
EP3433232B1 (en) 2020-07-15
BR112018069540A2 (pt) 2019-01-29
MY196355A (en) 2023-03-24
AR107964A1 (es) 2018-07-04
TN2018000269A1 (en) 2020-01-16
RS60857B1 (sr) 2020-10-30
PL3433232T3 (pl) 2020-12-14
AU2017238917A1 (en) 2018-08-16
JP2019509320A (ja) 2019-04-04
CA3014753A1 (en) 2017-09-28
PE20190169A1 (es) 2019-02-01
KR20170113040A (ko) 2017-10-12
HRP20201571T1 (hr) 2020-12-11
KR102417830B1 (ko) 2022-07-06
KR20200105771A (ko) 2020-09-09
ES2811478T3 (es) 2021-03-12
MA43832B1 (fr) 2020-08-31
CL2018002415A1 (es) 2018-12-28
PH12018501845A1 (en) 2019-05-15
JP6609065B2 (ja) 2019-11-20
EP3433232A4 (en) 2019-07-31
EP3433232A1 (en) 2019-01-30
DOP2018000191A (es) 2018-09-30
CN108602771A (zh) 2018-09-28
HK1254394A1 (zh) 2019-07-19

Similar Documents

Publication Publication Date Title
DOP2021000001A (es) Nueva sal de adición de ácido de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina
DOP2021000213A (es) Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composición farmacéutica que comprende los mismos
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
MX391440B (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
PE20190170A1 (es) Nueva forma cristalina de sal de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
MX2017015926A (es) Uso de derivados de bencimidazol para escape acido nocturno.
EA201790912A1 (ru) Гетероциклическое соединение
MX381944B (es) Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.
MX2017002385A (es) Metodos y reactivos para la prevencion y/o el tratamiento de infecciones.
MX389553B (es) Composicion para incrementar la expresion de pgc-1alfa
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
EA201890854A1 (ru) Иминосоединения с 2-хлорпиримидин-5-ильным заместителем в качестве средств борьбы с вредителями
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
EA201790453A3 (ru) Новая соль присоединения кислоты 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина
AR107164A1 (es) INHIBIDORES DE QUINASA p38
TH1801004904A (th) เกลือเพิ่มกรดแบบใหม่ของ 1-(5-(2,4-ไดฟลูออโรฟีนิล)-1-((3-ฟลูออโรฟีนิล)ซัลโฟนิล)-4-มีท็อกซี-1h-ไพร์โรล-3-อิล)-n-เมทิลมีเทนอะมีน
BR112018077078A2 (pt) composição para combater doenças do refluxo gastroesofágico